Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension
This study is to develop a predictive model for cardiocerebrovascular risk factors in elderly patients with essential hypertension with Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination.
- EligibilityCriteria: Inclusion Criteria:  A patient over 65-year-old with essential hypertension A patient with essential hypertension who require treatment with 3 or more antihypertensive medication, as determined by investigator's decision A patient with no MACCE within 6 months prior to the enrollment A patient who voluntarily signed the informed consent form  Exclusion Criteria:  A patient who participates in clinical trial A patient who are contraindicated for the Truset tablet according to the label. A patient who is unable to complete the study judged by the investigator. - HealthyVolunteers: No - Gender: All - MinimumAge: 65 Years - StdAgeList: Older Adult - StudyPopulation: Patients in General Hospital - SamplingMethod: Non-Probability Sample